HOME >> BIOLOGY >> NEWS
New target for HIV/AIDS drugs and vaccine discovered

Researchers from Rome, Italy, describe a finding in the August 2007 print issue of The FASEB Journal that could lead to new drugs to fight the HIV/AIDS virus, as well as new vaccines to prevent infection. It has been known that HIV proteins disable the antibody-forming part of the immune system (the homeland defense or acquired immune system). In this report, researchers demonstrate for the first time how the HIV-1 Nef viral protein delivers a one-two punch to the bodys innate immune system (our early warning system composed of dendritic and natural killer cells). First, Nef hijacks dendritic cells (DCs) to upset the function of natural killer (NK) cells. Second, after blocking this first line of defense against the immune system, Nef uses DCs and NK cells to create a microenvironment that actually makes it easier for HIV/AIDS to replicate.

According to Maria Giovanna Quaranta of Instituto Superiore de Sanit and first author of the article, The findings described in this work may have several implications for AIDS treatment: the understanding of Nef function, mechanism of action, and cellular partners might aid the discovery of suitable drugs able to block the activity of this smart protein. Quaranta added, An exciting possibility is the design of a vaccine including a mutated Nef protein unable to assist the virus in the control of its host.

The research findings also raise another intriguing possibility: Nef proteins may be able to boost or suppress DC and NK cell activity. If so, it may prove to be a valuable new therapeutic approach for people with diseases and disorders that involve overactive or underactive immune responses. DCs and NK cells play critical roles in the bodys initial defense against infection. DCs are instrumental in identifying foreign invaders to the body and then orchestrating an immune response that ultimately removes them. NK cells are among the first cells summoned by DCs to help isolate and contain the infection un
'"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
26-Jul-2007


Page: 1 2

Related biology news :

1. Huntingtons disease study shows animal models on target
2. When off-target is right on
3. Genomic analysis uncovers new targets for HIV vaccine
4. Bulls-eye -- Programs targeting math, science teacher shortage may get boost
5. Scientists take next step in understanding potential target for ovarian cancer treatment
6. On target
7. New way to target and kill antibiotic-resistant bacteria found
8. Weill Cornell team identifies potential new cancer drug target
9. CSHL scientists successfully target tumor microenvironment to stop cancer growth
10. Sleep deprivation affects airport baggage screeners ability to detect rare targets
11. Genomic signatures identify targeted therapies for lung cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/26/2020)... ... August 24, 2020 , ... ... chronic inflammatory and fibrotic diseases, today announced that Dr. Stacie Canan has joined ... , Dr. Canan previously served as Executive Director of Global Health at Bristol ...
(Date:8/21/2020)... ... August 18, 2020 , ... Sentien ... announced that the U.S. Food and Drug Administration (FDA) has approved the company’s ... for the treatment of severe COVID-19. Approval of this IND allows Sentien to ...
(Date:8/12/2020)... ... August 12, 2020 , ... Mosio recently ... ideal for public health agencies of all sizes. With a focus on tracking ... individuals find appropriate health care, Mosio helps public health departments automate communications and ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... ... August 11, 2020 , ... The FSHD Society ... Muscular Dystrophy Clinical Trial Research Network (FSHD CTRN), with consideration of ... a consortium of academic research centers in the United States and Europe with ...
(Date:8/7/2020)... ... August 06, 2020 , ... VGXI, a highly ... closed on the purchase of greenfield for a new, expanded manufacturing facility. The ... 21 acres in the initial acquisition, with an option to purchase an additional ...
(Date:7/31/2020)... ... ... R3 Stem Cell International is now offering patients the opportunity to receive four ... may choose which extremities they would like treated. , Several studies have shown just ... R3 International, umbilical cord tissue is obtained from a lab with a long history ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... up to three different materials for use with CRM, neurostimulation, vascular, and related ... materials to meet specific design requirements, performance, and cost criteria; especially where solid ...
Breaking Biology Technology:
Cached News: